20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Alpha Tau Medical Ltd (DRTS) operates in the BIOTECHNOLOGY industry and is headquartered in Jerusalem, Israel with about 121 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, DRTS reported $0M in revenue and ($43M) in net income.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($1M) | ($1M) | ($1M) | ($1M) | ($1M) | $0M | — |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($50M) | ($42M) | ($36M) | ($36M) | ($32M) | ($14M) | ($9M) | ($8M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($93M) | ($43M) | ($32M) | ($29M) | ($34M) | ($27M) | ($9M) | ($8M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($49M) | ($41M) | ($30M) | ($28M) | ($31M) | ($13M) | ($9M) | ($8M) |
| Earnings Per Share (EPS) | $-1.04 | $-0.53 | $-0.45 | $-0.42 | $-0.53 | $-0.40 | $-0.13 | $-0.13 |
| Shares Outstanding (M) | 91M | 81M | 70M | 69M | 64M | 68M | 68M | 68M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($14M) | ($13M) | ($13M) | ($11M) | ($10M) | ($9M) | ($10M) | ($8M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($46M) | ($23M) | ($12M) | ($12M) | ($10M) | ($9M) | ($9M) | ($7M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($14M) | ($13M) | ($11M) | ($11M) | ($9M) | ($9M) | ($5M) | ($8M) |
| Earnings Per Share (EPS) | $-0.50 | $-0.26 | $-0.14 | $-0.14 | $-0.13 | $-0.12 | $-0.14 | $-0.10 |
| Shares Outstanding (M) | 91M | 90M | 86M | 85M | 80M | 70M | 70M | 70M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | — | ($27M) | ($20M) | ($18M) | ($24M) | ($12M) | ($7M) | ($7M) |
| Capital Expenditures (CapEx) | $6M | $6M | $2M | $6M | $1M | $3M | $4M | $1M |
| Free Cash Flow (FCF) | — | ($33M) | ($22M) | ($24M) | ($25M) | ($15M) | ($11M) | ($8M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2025-12-31 |
|---|---|
| Cash from Operations (CFO) | ($27M) |
| Capital Expenditures (CapEx) | $6M |
| Free Cash Flow (FCF) | ($33M) |
| FCF Margin % | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $134M | $107M | $86M | $107M | $120M | $42M | $53M | $32M |
| Cash & Cash Equivalents | $23M | $16M | $14M | $13M | $6M | $23M | $16M | $2M |
| Total Liabilities | $90M | $29M | $24M | $23M | $14M | $77M | $61M | $32M |
| Total Debt (Short + Long-Term) | $8M | $7M | $7M | $7M | $1M | $0M | $0M | $0M |
| Total Shareholders' Equity | $44M | $77M | $63M | $84M | $106M | ($35M) | ($8M) | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DRTS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms